Target Name: VGLL4
NCBI ID: G9686
Other Name(s): vestigial like family member 4 | Vestigial-like 4 | Transcription cofactor vestigial-like protein 4 | KIAA0121 | Vestigial like family member 4, transcript variant 1 | VGLL4 variant 1 | Vestigial like 4 | VGLL4_HUMAN | Vgl-4 | VGL-4 | vestigial like 4 | Transcription cofactor vestigial-like protein 4 (isoform a)

VGLL4: A Potential Drug Target and Biomarker

Vestigial like family member 4 (VGLL4) is a gene that has been identified in various organisms, including humans. It has been annotated as a potential drug target and biomarker. In this article, we will explore the potential implications of VGLL4 as a drug target and biomarker.

Drug Target Potential

VGLL4 is a gene that has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. It is also known to be involved in the development and progression of various diseases, including cancer. Therefore, it is a promising target for drug development.

One of the potential drug targets for VGLL4 is the inhibition of its activity, as this could lead to the regression of cancer cells and the inhibition of their migration and invasion. This could be achieved through various mechanisms, such as blocking the VGLL4-FGF signaling pathway, which is known to be involved in cancer cell growth and progression.

Another potential mechanism for the inhibition of VGLL4 could be the inhibition of its expression. This could be achieved through the use of small molecules, such as inhibitors, or through the use of antibodies that target VGLL4 specifically.

Biomarker Potential

VGLL4 has also been identified as a potential biomarker for various diseases, including cancer. This is because its expression is often affected by the progression of these diseases. For example, it has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers.

Additionally, VGLL4 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Therefore, it may also be a potential biomarker for these diseases.

Conclusion

In conclusion, VGLL4 is a gene that has been identified as a potential drug target and biomarker. Its expression is involved in various cellular processes, including cell adhesion, migration, and invasion, and it has been shown to be involved in the development and progression of various diseases, including cancer. Therefore, it is a promising target for drug development and a potential biomarker for various diseases. Further research is needed to fully understand its potential mechanisms of action and its potential as a drug and biomarker.

Protein Name: Vestigial Like Family Member 4

Functions: May act as a specific coactivator for the mammalian TEFs

More Common Targets

VHL | VIL1 | VILL | VIM | VIP | VIPAS39 | VIPR1 | VIPR1-AS1 | VIPR2 | VIRMA | VIT | VKORC1 | VKORC1L1 | VLDLR | VLDLR-AS1 | VMA21 | VMAC | VMO1 | VMP1 | VN1R1 | VN1R101P | VN1R108P | VN1R10P | VN1R11P | VN1R12P | VN1R17P | VN1R18P | VN1R2 | VN1R4 | VN1R46P | VN1R5 | VN1R82P | VN1R91P | VN1R96P | VN2R11P | VN2R1P | VN2R3P | VNN1 | VNN2 | VNN3P | Voltage-dependent anion channels (Porins) | Voltage-dependent calcium channel gamma subunit | Voltage-gated K(v) channel | Voltage-Gated Sodium Channel Complex | Volume-Regulated Anion Channel (VRAC) | VOPP1 | VOR Complex | VPREB1 | VPREB3 | VPS11 | VPS13A | VPS13A-AS1 | VPS13B | VPS13C | VPS13C-DT | VPS13D | VPS16 | VPS18 | VPS25 | VPS26A | VPS26AP1 | VPS26B | VPS26C | VPS28 | VPS29 | VPS33A | VPS33B | VPS35 | VPS35L | VPS36 | VPS37A | VPS37B | VPS37C | VPS37D | VPS39 | VPS41 | VPS45 | VPS4A | VPS4B | VPS50 | VPS51 | VPS51P8 | VPS52 | VPS53 | VPS54 | VPS72 | VPS8 | VPS9D1 | VPS9D1-AS1 | VRK1 | VRK2 | VRK3 | VRTN | VSIG1 | VSIG10 | VSIG10L | VSIG10L2 | VSIG2 | VSIG4 | VSIG8